INTRODUCTION {#s1}
============

The tumor--node--metastasis (TNM) staging has been the global standard for estimating cancer cell dissemination \[[@R1]\]. Nonetheless, TNM classification alone is not sufficient in predicting cancer outcomes because various factors, including tumor characteristics, systemic inflammation, and nutritional status, are involved in tumor progression \[[@R2], [@R3]\].

The impact of the nutritional status on the outcome of cancer patients has been intensively studied in recent years, and several assessment tools have been proposed for nutritional screening \[[@R4]\]. However, the usefulness of these tools has not been fully evaluated in elderly patients. The geriatric nutritional risk index (GNRI) was developed as a simple and objective nutritional assessment tool for hospitalized elderly patients (aged ≥ 65 years, according to World Health Organization definition of elderly; <https://www.who.int/>) based on their body weight and serum albumin level \[[@R5]\]. Albumin is affected by age-related changes such as hydration and hepatic and renal dysfunction \[[@R6]--[@R8]\]. In addition, body weight appears to be a good indicator of both the severity of systemic illness and the amount of protein-calorie stores \[[@R9], [@R10]\]. We, therefore, believe that the GNRI accurately reflects the nutritional status of elderly cancer patients who are at risk of malnutrition because of their physiological frailty and vulnerability.

The principal aim of this study was to evaluate the prognostic significance of the preoperative GNRI for estimating the postoperative outcomes of elderly gastric cancer patients.

RESULTS {#s2}
=======

GNRI and clinicopathological features {#s2_1}
-------------------------------------

The relationship between the GNRI values and the clinicopathological characteristics of the 297 patients enrolled in this study is summarized in [Table 1](#T1){ref-type="table"}. Based on the GNRI cutoff value for overall survival (OS), 97 (32.7%) and 200 (67.3%) patients were classified as having a low or high GNRI, respectively. There was a significant association between the GNRI and clinicopathological factors such as age (*p* \< 0.001), body mass index (BMI) (*p* \< 0.001), American Society of Anesthesiologists physical status (ASA-PS) (*p* = 0.014), red blood cell (RBC) count (*p* \< 0.001), albumin (*p* \< 0.001), C-reactive protein (CRP) (*p* \< 0.001), tumor size (*p* \< 0.001), tumor differentiation (*p* = 0.021), depth of tumor (*p* \< 0.001), pathological stage (*p* \< 0.001), and intraoperative blood loss (*p* = 0.048).

###### Relationships between GNRI and clinicopathological features in all elderly patients with gastric cancer

  Characteristics               Number of patients   GNRI (based on OS)   GNRI (based on CSS)                                                       
  ----------------------------- -------------------- -------------------- --------------------- ---------- -------------------- ------------------- ----------
  Age (years old)                                    79 (65--91)          74 (65--89)           \< 0.001   79 (65--91)          75 (65--89)         \< 0.001
  Gender                                                                                        0.601                                               0.441
   Male                         205                  65                   140                              43                   162                 
   Female                       92                   32                   60                               23                   69                  
  BMI                                                20.8 (14.7--30.5)    22.9 (16.5--40.4)     \< 0.001   20.1 (14.7--30.5)    22.8 (16.5--40.4)   \< 0.001
  ASA-PS                                                                                        0.014                                               0.069
   1                            8                    0                    8                                0                    8                   
   2                            256                  80                   176                              54                   202                 
   ≥ 3                          33                   17                   16                               12                   21                  
  WBC (μl)                                           5450 (1830--13700)   5695 (510--9830)      0.260      5520 (1830--13700)   5680 (510--10300)   0.833
  RBC (× 10^4^ μl)                                   365 (142--570)       435 (203--579)        \< 0.001   367 (142--570)       427 (203--579)      \< 0.001
  Albumin (g/dl)                                     3.4 (1.1--4.0)       4.2 (3.6--5.0)        \< 0.001   3.2 (1.1--3.9)       4.1 (3.4--5.0)      \< 0.001
  CRP (mg/l)                                         0.16 (0.01--11.1)    0.07 (0.01--7.09)     \< 0.001   0.24 (0.01--11.1)    0.07 (0.01--7.09)   \< 0.001
  Location of tumor                                                                             0.119                                               0.510
   EGJ                          11                   1                    10                               1                    10                  
   U                            53                   22                   31                               15                   38                  
   M                            122                  35                   87                               26                   96                  
   L                            111                  39                   72                               24                   87                  
  Tumor size (mm)                                    58 (7--180)          36 (3--176)           \< 0.001   60 (7--170)          40 (3--180)         \< 0.001
  Procedure                                                                                     0.118                                               0.043
   LTG                          63                   27                   36                               21                   42                  
   LPG                          29                   7                    22                               4                    25                  
   L(A)DG                       205                  63                   142                              41                   164                 
  Tumor differentiation                                                                         0.021                                               0.101
   Well                         65                   12                   53                               9                    56                  
   Moderate                     120                  43                   77                               26                   94                  
   Poor                         112                  42                   70                               31                   81                  
  Depth of tumor                                                                                \< 0.001                                            \< 0.001
   T1a-1b                       145                  31                   114                              19                   126                 
   2                            44                   12                   32                               7                    37                  
   3                            44                   24                   20                               17                   27                  
   4a-4b                        64                   30                   34                               23                   41                  
  Lymph node metastasis                                                                         0.145                                               0.158
   N0                           192                  57                   135                              38                   154                 
   N1                           38                   11                   27                               8                    30                  
   N2                           35                   17                   18                               13                   22                  
   N3                           32                   12                   20                               7                    25                  
  Pathological stage                                                                            \< 0.001                                            \< 0.001
   1a-1b                        171                  38                   133                              24                   147                 
   2a-2b                        53                   26                   27                               18                   35                  
   3a-3c                        73                   33                   40                               24                   49                  
  Operation time (min)                               390 (204--911)       409 (70--808)         0.396      392 (204--911)       406 (70--808)       0.643
  Intraoperative blood loss                          100 (0--1600)        45 (0--4070)          0.048      125 (0--1600)        50 (0--4070)        0.029
  CEA (ng/ml)                                        3.4 (0.8--163.3)     3.4 (0.7--161.1)      0.314      3.7 (0.8--163.3)     3.3 (0.7--161.1)    0.078
  Postoperative complications                                                                   0.292                                               0.387
   absent                       202                  62                   140                              42                   160                 
   present                      95                   35                   60                               24                   71                  
  Adjuvant chemotherapy                                                                         0.737                                               0.888
   Yes                          79                   27                   52                               18                   61                  
   No                           218                  70                   148                              48                   170                 

Abbreviations: OS: overall survival, CSS: cancer-specific survival, GNRI: geriatric nutritional risk index, BMI: body mass index, ASA-PS: American Society of Anesthesiologists physical status, WBS: white blood cell, RBC: red blood cell, CRP: C-reactive protein, EGJ: esophagogastric junction, U: upper part, M: middle part, L: lower part, CEA: carcinoembryonic antigen, LTG: laparoscopic total gastrectomy, LPG: laparoscopic proximal gastrectomy, L(A)Dg: laparoscopic (assisted) distal gastrectomy.

Based on the GNRI cutoff value for cancer-specific survival (CSS), 66 (22.2%) and 231 patients (77.8%) were classified as having a low or high GNRI, respectively. GNRI values were significantly associated with age (*p* \< 0.001), BMI (*p* \< 0.001), RBC (*p* \< 0.001), albumin (*p* \< 0.001), CRP (*p* \< 0.001), tumor size (*p* \< 0.001), operative procedure (*p* = 0.043), depth of tumor (*p* \< 0.001), pathological stage (*p* \< 0.001), and intraoperative blood loss (*p* = 0.029).

Analysis based on the GNRI cutoff value for OS and CSS showed no causal relationship between GNRI values and postoperative complication rates.

Cox regression analysis of OS {#s2_2}
-----------------------------

In univariate analyses, OS was found to be significantly associated with ASA-PS (*p* \< 0.001), tumor size (*p* = 0.018), tumor differentiation (*p* \< 0.001), pathological stage (*p* \< 0.001), carcinoembryonic antigen (CEA) (*p* = 0.005), CRP (*p* = 0.030), postoperative complications (*p* = 0.002), and GNRI (*p* \< 0.001). Multivariate analysis revealed that ASA-PS (hazard ratio \[HR\]: 3.755; 95% confidence interval \[CI\]: 2.130--6.619; *p* \< 0.001), tumor differentiation (HR: 1.798; 95% CI: 1.132--2.857; *p* = 0.013), pathological stage (HR: 2.028; 95% CI: 1.176--3.498; *p* = 0.011), and GNRI (HR: 2.350; 95% CI: 1.436--3.847; *p* \< 0.001) were significant independent prognostic factors of OS ([Table 2](#T2){ref-type="table"}).

###### Univariate and multivariate analyses of clinicopathological factors for overall survival

  Variables              Category or characteristics   Patients    Univariate analysis   Multivariate analysis                                     
  ---------------------- ----------------------------- ----------- --------------------- ----------------------- ---------- ------- -------------- ----------
  Gender                 (female/male)                 92/205      1.158                 0.718--1.866            0.547                             
  ASA-PS                 (\< 3 / ≥ 3)                  264/33      3.937                 2.306--6.721            \< 0.001   3.755   2.130--6.619   \< 0.001
  BMI                    (≥ 18.5 / \< 18.5)            269/28      1.652                 0.874--3.122            0.122                             
  Tumor size             (\< 5 / ≥ 5)                  163/134     1.706                 1.097--2.653            0.018      1.123   0.641--1.970   0.685
  Differentiation        (well & mod/poor)             184/113     2.132                 1.375--3.305            \< 0.001   1.798   1.132--2.857   0.013
  Pathological stage     (1,2/3)                       224/73      2.720                 1.751--4.225            \< 0.001   2.028   1.176--3.498   0.011
  CEA                    (\< 5.0 / ≥ 5.0)              225/72      1.936                 1.222--3.066            0.005      1.593   0.993--2.557   0.054
  CRP                    (≦ 0.5 / \> 0.5)              248/49      1.750                 1.055--2.904            0.030      1.170   0.656--2.088   0.595
  GNRI                   (\> 94.8 / \< 94.8)           200/97      2.470                 1.596--3.823            \< 0.001   2.350   1.436--3.847   \< 0.001
  Complications          (absent/present)              202/95      1.985                 1.275--3.089            0.002      1.532   0.961--2.440   0.073
  Intraope. blood loss   (\< 50 / ≥ 50)                (163/134)   1.615                 0.998 -- 2.615          0.051                             
  Adjuvant Chemo         (no/yes)                      218/79      1.544                 0.979--2.434            0.062                             

Abbreviations: HR: hazard ratio, CI: confidence interval, ASA-PS: American Society of Anesthesiologists physical status, BMI: body mass index, mod: moderately, poor: poorly, CEA: carcinoembryonic antigen, CRP: C-reactive protein, GNRI: geriatric nutritional risk index, Complications: postoperative complications, Intraope. blood loss: intraoperative blood loss, Adjuvant chemo: adjuvant chemotherapy.

Cox regression analysis of CSS {#s2_3}
------------------------------

The univariate analyses identified that CSS was significantly associated with ASA-PS (*p* = 0.014), tumor size (*p* = 0.001), tumor differentiation (*p* = 0.012), pathological stage (*p* \< 0.001), CEA (*p* = 0.002), postoperative adjuvant chemotherapy (*p* \< 0.001), and GNRI (*p* = 0.006). The ASA-PS (HR: 3.034; 95% CI: 1.272--7.234; *p* = 0.012), pathological stage (HR: 4.178; 95% CI: 1.714--10.183; *p* = 0.002), and CEA (HR: 1.995; 95% CI; 1.016--3.914; *p* = 0.045) were significant independent prognostic factors of CSS in the multivariate analysis. However, the GNRI was not confirmed to be an independent prognostic factor for CSS ([Table 3](#T3){ref-type="table"}).

###### Univariate and multivariate analyses of clinicopathological factors for cancer-specific survival

  Variables              Category or characteristics   Patients    Univariate analysis   Multivariate analysis                                      
  ---------------------- ----------------------------- ----------- --------------------- ----------------------- ---------- ------- --------------- -------
  Gender                 (female/male)                 92/205      1.433                 0.673--3.048            0.351                              
  ASA                    (\< 3 / ≥ 3)                  264/33      2.839                 1.237--6.519            0.014      3.034   1.272--7.234    0.012
  BMI                    (≥ 18.5 / \< 18.5)            269/28      1.381                 0.487--3.913            0.544                              
  Tumor size             (\< 5 / ≥ 5)                  163/134     3.339                 1.605--6.946            0.001      1.366   0.567--3.291    0.487
  Differentiation        (well & mod/poor)             184/113     2.335                 1.203--4.530            0.012      1.264   0.616--2.594    0.523
  Pathological stage     (1,2 / 3)                     224/73      7.720                 3.796--15.699           \< 0.001   4.178   1.714 -10.183   0.002
  CEA                    (\< 5.0 / ≥ 5.0)              225/72      2.773                 1.436--5.357            0.002      1.995   1.016--3.914    0.045
  CRP                    (≦ 0.5 / \> 0.5)              248/49      1.566                 0.712--3.444            0.264                              
  GNRI                   (\> 90.9 / \< 90.9)           231/66      2.578                 1.318--5.043            0.006      1.754   0.849--3.625    0.129
  Complications          (absent/present)              202/95      1.706                 0.872--3.339            0.119                              
  Intraope. blood loss   (\< 50 / ≥ 50)                (163/134)   1.989                 0.955 -- 4.141          0.066                              
  Adjuvant chemo         (no/yes)                      218/79      4.190                 2.142--8.198            \< 0.001   1.761   0.795--3.900    0.163

Abbreviations: HR: hazard ratio, CI: confidence interval, ASA-PS: American Society of Anesthesiologists physical status, BMI: body mass index, mod: moderately, poor: poorly, CEA: carcinoembryonic antigen, CRP: C-reactive protein, GNRI: geriatric nutritional risk index, Complications: postoperative complications, Intraope. blood loss; intraoperative blood loss, Adjuvant chemo: adjuvant chemotherapy.

Postoperative OS analysis stratified by the GNRI {#s2_4}
------------------------------------------------

Kaplan--Meier analysis and the log-rank test demonstrated that patients with a low GNRI had a significantly worse prognosis in terms of OS than those with a high GNRI (*p* \< 0.001). The 5-year OS rates for patients with low and high GNRI values were 52.2% and 78.9%, respectively ([Figure 1](#F1){ref-type="fig"}).

![Kaplan--Meier curves of postoperative OS based on GNRI in all elderly gastric cancer patients.](oncotarget-11-2345-g001){#F1}

In the stratified analysis according to pTNM stage, patients with low GNRI only in pTNM stage I had a significantly worse OS compared with patients with normal GNRI (*p* \< 0.001); however, no significant differences were found among gastric cancer patients with pTNM stage II and III ([Figure 2A](#F2){ref-type="fig"}--[2C](#F2){ref-type="fig"}).

![Overall survival curves based on GNRI according to pTNM stage.\
(**A**) pTNM stage I (*n* = 171), (**B**) pTNM stage II (*n* = 53), (**C**) pTNM stage III (*n* = 73).](oncotarget-11-2345-g002){#F2}

Postoperative CSS analysis stratified by the GNRI {#s2_5}
-------------------------------------------------

Kaplan--Meier analysis and the log-rank test revealed a worse prognosis in terms of CSS in patients with a low GNRI than those with a high GNRI (*p* = 0.004). The 5-year CSS rates for patients with low and high GNRI values were 73.2% and 88.4%, respectively ([Figure 3](#F3){ref-type="fig"}).

![Kaplan--Meier curves of postoperative CSS based on GNRI in all gastric cancer patients.](oncotarget-11-2345-g003){#F3}

The stratified analysis according to pTNM stage showed that patients with low GNRI had significantly worse CSS than patients with normal GNRI only in pTNM stage I (*p* = 0.006); however, there were no significant differences among gastric cancer patients with pTNM stage II and III ([Figure 4A](#F4){ref-type="fig"}--[4C](#F4){ref-type="fig"}).

![Cancer-specific survival curves based on GNRI according to pTNM stage.\
(**A**) pTNM stage I (*n* = 171), (**B**) pTNM stage II (*n* = 53), (**C**) pTNM stage III (*n* = 73).](oncotarget-11-2345-g004){#F4}

DISCUSSION {#s3}
==========

Malnutrition is a very common problem among the elderly. It is caused by age-related physical, psychological, or physiological changes \[[@R11]\], leading to diminished quality of life, performance status, immune function, and resistance to infections \[[@R12], [@R13]\]. Furthermore, malnutrition is particularly common in patients with gastrointestinal cancer because the disease mechanically inhibits the oral intake of food and/or directly impairs digestion either through local or systemic effects.

Several nutritional assessment tools have been developed to predict the prognosis of cancer patients, including the Glasgow Prognostic Score (GPS), the Controlling Nutritional Status (CONUT) score, and the Prognostic Nutritional Index (PNI) \[[@R14]--[@R16]\]. However, the clinical application of these tools in elderly cancer patients is limited because of the lack of consensus regarding their usefulness. The GNRI was originally developed as an objective and simple nutritional screening tool to evaluate the nutrition-related risks of hospitalized elderly patients. Patients were divided into four groups based on the GNRI values: high risk (GNRI \< 82), moderate risk (GNRI 82--92), low risk (GNRI 92--98), and normal level (GNRI \> 98) \[[@R5]\]. However, in this study, the long-term outcome of gastric cancer patients was examined regardless of their hospitalization status in order to create a cutoff value using receiver operating characteristic (ROC) analysis. Patients have also been classified into the low- and high-GNRI groups, and an association between low GNRI and mortality in elderly patients with chronic obstructive pulmonary disease, chronic kidney disease, or chronic heart failure was recently reported \[[@R17]--[@R20]\]. However, the use of the GNRI for cancer patients is not fully standardized, and its availability is limited because of the small number of studies reported.

In other contexts, GNRI has been reported as a useful tool for screening nutritional status, which is commonly determined using albumin and body weight loss \[[@R5]\]. Albumin stabilizes cell growth and DNA replication, participates in a variety of biochemical changes, protects against tumorigenesis, and maintains sex hormone homeostasis. Generally, hypoalbuminemia is commonly recognized in elderly populations caused by poor dietary intake, protein loss, or catabolic metabolism; therefore, albumin can reflect the inflammation and immune status of cancer cells \[[@R21], [@R22]\]. Likewise, most elderly patients are malnourished because of poor dietary intake, protein loss, or catabolic metabolism. Malnutrition is a complex state that is often related to functional impairment, disability, poor health, and aging, resulting in protein and energy deficiency, energy collapse, and impaired immunity. BMI, which considers the body weight and height, is also commonly used to assess an individual's nutritional status \[[@R23], [@R24]\]. Therefore, GNRI, which is based on the combination of albumin and BMI, is a more accurate predictor of nutritional status than either of these parameters alone. As expected, a low GNRI adversely affected OS after laparoscopic gastrectomy in gastric cancer patients aged 65 or older in this study. However, it did not affect CSS. Although the mechanisms by which GNRI affects only provisional OS and not CSS is difficult to clarify, the possible reasons could be the increase in oral intake disorders that tends to occur with aging results in hypoalbuminemia and malnutrition \[[@R25]\]; cancer promotes inflammation and impairs nutrient absorption by increasing the production of catabolic cytokines, which accelerate malnutrition \[[@R26], [@R27]\]; and aging itself is associated with a systemic chronic low-grade inflammation; hence, a vicious cycle of malnutrition and inflammation occurs in gastric cancer patients, especially in the elderly \[[@R28]--[@R30]\]. We, therefore, believe that the GNRI can accurately predict OS because it reflects the integrated nutritional status associated with cancer progression and other age-related catabolic reactions.

In the future, the potential cancer-specific predictability of other prognostic nutritional scores such as the GPS, CONUT, and PNI, which consider albumin and other immune-nutritional factors, should be validated. Recently, several studies have indicated that a systemic inflammatory response may be associated with poor outcome in patients with advanced cancer. In particular, the GPS, an inflammation-based prognostic score that includes CRP and albumin, is one of the most useful scoring systems for prognosticating patients with various advanced cancers \[[@R31], [@R32]\]. CONUT, which is calculated using albumin, total lymphocyte, and total cholesterol, comprehensively reflects the balance between host inflammatory and immune responses because cholesterol is used as a parameter of caloric storage and lymphocyte is used as an indicator of immune status \[[@R16], [@R33]\]. Additionally, PNI, which is based on lymphocyte and albumin, was originally reported as a nutritional assessment tool for predicting the risk of operative morbidity after gastrointestinal surgery. Currently, PNI can be considered a good indicator of prognosis and the immune and nutritional status of patients with cancer \[[@R34], [@R35]\].

This study has some limitations that should be considered when interpreting the results. First, this study has a small sample size, which accounts for the lack of statistical power, and thus, we were unable to obtain sufficient information on preoperative comorbidities. To draw a better conclusion, a multicenter, large-scale study is needed to establish the role of GNRI as a prognostic predictor in patients with gastric cancer. Second, there are no consensual cutoff values for GNRI in predicting OS. The universal cutoff value should be verified in prospective and well-designed randomized controlled trials before it is adopted in routine practice. Third, the definition of elderly population is not consistent among researchers. Finally, GNRI has not been compared with other nutritional assessment tools; therefore, future prospective randomized studies are warranted to investigate the significance of preoperative nutritional intervention for improving surgical outcome in gastric cancer patients.

This study evaluated the association between preoperative GNRI and long-term outcomes in elderly gastric cancer patients. The GNRI, which was originally developed as an objective and simple nutritional screening tool to evaluate the nutrition-related risk index in elderly hospitalized patients, has been reported to be associated with mortality in elderly patients with chronic obstructive pulmonary disease, chronic kidney disease, and/or chronic heart failure. However, this is one of the few studies that assessed the use of GNRI for elderly patients with gastric cancer. In conclusion, GNRI proved to be a promising candidate not only for assessing the nutritional status of hospitalized elderly patients but also for predicting OS in elderly gastric cancer patients after laparoscopic gastrectomy because it reflects the integrated nutritional status associated with cancer progression and age-related catabolic reactions. When deciding a treatment strategy for cancer patients, tumor- and host-related factors should be considered. Recently, GNRI has been reported as an accurate tool to assess the risk of patients with chronic obstructive pulmonary disease, with cardiovascular disease, undergoing hemodialysis, and with chronic renal failure. In Japan, which has an aging society, individualized treatment strategy for gastric cancer is indispensable because there are many deaths caused by other diseases. Recently, sarcopenia has been reported to affect the incidence of adverse events with chemotherapy and the continuation of treatment, leading to worse prognosis. Sarcopenia, the age-related loss of skeletal muscle mass and strength, was identified based on cross-sectional computed tomography images at the L3 level \[[@R36]\]. However, GNRI can be easily calculated from routine laboratory data and physical measurements. The clinical significance of GNRI, as an indicator of OS, will be increasingly important in the future.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

We conducted a retrospective analysis of elderly patients with gastric cancer who underwent curative laparoscopic (assisted) gastrectomy at our institute between January 2010 and December 2017. The inclusion criteria were age ≥ 65 years (according to the World Health Organization's definition of elderly; <https://www.who.int/>), histologically verified gastric adenocarcinoma, no distant metastasis, Eastern Cooperative Oncology Group performance status ≤ 2, and curative gastrectomy. The exclusion criteria were remnant gastric cancer, T4b disease, emergency gastrectomy for bleeding or perforation, mortality related to surgery within 30 days, and coexisting hematological, inflammatory, or autoimmune disorders. Based on these inclusion and exclusion criteria, a total of 297 patients were enrolled in the study. Our study was approved by the Ethical Review Board of the Shimane University Faculty of Medicine, Shimane, Japan (authorization number: 4011).

Outcome evaluation {#s4_2}
------------------

The median follow-up time was 36.0 months (range: 2.8--96.5 months) in all patients after gastrectomy.

The observation period started on the date of gastrectomy and ended on the date of death, last follow-up, or withdrawal of consent. OS and CSS were assessed based on the cause of death as determined from manual or computerized records. OS was calculated using the period from the date of primary gastrectomy to the date of death from any cause or last follow-up. CSS was defined as the interval from the date of surgery to cancer-related death or withdrawal of consent.

The pathological stage was assigned in accordance with the TNM classification (7th edition) \[[@R1]\]. We categorized postoperative complications according to the Clavien--Dindo (CD) classification, and postoperative complications were defined as grade II or higher \[[@R37]\].

GNRI calculation {#s4_3}
----------------

Preoperative laboratory data, including the GNRI, and physical measurements were obtained in each patient within 7 days prior to surgery.

The GNRI was developed by combining two nutritional indicators: albumin and actual weight compared with ideal body weight. The GNRI formula is as follows: GNRI = \[1.487 × serum albumin (g/L)\]+\[41.7 × actual/usual body weight) (kg)\]. The formula for the ideal body weight is as follows: ideal body weight (kg) = 22 × square of height (m^2^) \[[@R5]\]. When the patient's actual BW is greater than the ideal BW, the ratio of the actual BW to the ideal BW was 1.

A ROC curve was generated to verify the optimal cutoff value of preoperative GNRI for predicting OS and CSS. The ability of GNRI to predict OS and CSS was evaluated using the area under the ROC curve (AUC) estimation method. The GNRI ranged from 54.4 to 117.6, and the mean GNRI was 98.5. The median GNRI was 99.9. The optimal cutoff value for preoperative GNRI was set at 94.8 for OS (sensitivity, 54.3%; specificity, 75.0%; AUC = 0.694) and 90.9 for CSS (sensitivity, 41.7%; specificity, 80.1%; AUC = 0.599). Patients were categorized as having a low or high GNRI based on the cutoff values ([Figure 5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}).

![ROC for GNRI as a predictive factor for postoperative survival was plotted to verify the optimum cutoff value of GNRI.\
(**A**) overall survival, (**B**) cancer-specific survival.](oncotarget-11-2345-g005){#F5}

Statistical analysis {#s4_4}
--------------------

Comparisons were performed using the chi-square test or Student's *t*-test for categorical variables and the Mann--Whitney *U* test for non-normally distributed continuous variables. The OS and CSS were calculated using the Kaplan--Meier method, and the differences between the survival curves were assessed by the log-rank test.

Univariate analyses were also performed to identify variables that were significantly associated with OS or CSS, and variables with a univariate *p* value \< 0.05 were included in the multivariate analysis, for which a Cox proportional hazards model was used. JMP version 14 (SAS Institute, Cary, NC, USA) was used for the statistical analyses.
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